Genzyme

Those target markets who rely on Johnson & Johnson health and medical needs are mostly patients, doctors, nurses and civilians. Therefore, the company need to sustain their products and services over all these years to ensure that lower income people and underprivileged patients are able to access on their medicines. This however requires the company to balance patient’s access and competitive dynamics in line with their need as the company need to have enough resources to keep on being innovating, creating new and better medicines and at the same time making sure there will be a fair return to the shareholder as well. Johnson & Johnson also work closely with the governments, physicians, non-government organizations and the international donors all around the world to provide its products within an affordable prices to its

TB is still proven to be a top killer around the world, and with more cases of drug resistant TB being reported daily, the cost of treating and preventing this disease will continue to be on the rise.

While tuberculosis was never completely eliminated, there was a significant drop in cases and death rates, as a result of the BCG vaccine and new anti-tubercular drugs in the 1950’s.

Tuberculosis has been part of human history for a long time but how long is a long time? Recent research using genetic data has allowed us to know that the tuberculosis progenitor has been on this planet for about 3 million years affecting even our earlier ancestors (Gutierrez et al, 2005). Additionally this research showed that the bacilli from tuberculosis are capable of mixing sections of their genome with other strains and giving the pathogen a composite assembly, which resulted from ancient horizontal exchanges before its clonal expansion. This quality provided tuberculosis a big advantage that even now a days allows the organism to evade, adapt and create resistance to treatments that were once successful. In order to fix current and

What is unknown to many is that The CDC (Centers for Disease Control) is in the vaccine business. Members

The Stop TB Partnership Japan (STBJ) (2014) states in its action plan that its primary implementations for Japan are to strengthen support for high risk groups such as the elderly and those with social risk factors and to provide an efficient system to cultivate medical staff.

Tuberculosis, the white plague as used to be called once upon a time is still one of the deadliest bacterial killers affecting almost all parts, all corners of the globe. Though successful anti-tubercular antibiotic regimens and effective vaccine are available for decades and being used in the battle against Koch’s bacillus, Mycobacterium tuberculosis, the causative agent of this chronic multi organ granulomatous disease, our strand in the battle continuously seems to be in the losing side. Moreover the increasing prevalence of HIV-AIDS and diabetes mellitus is being proved to be providing predisposition to tuberculosis. As witnessed by the WHO, which has estimated that, in the year 2012, 8.6 million people have developed tuberculosis and 1.3 million have died of the disease including 320000 deaths of HIV-TB co-infected people (Global tuberculosis report 2013. World Health Organization; 2013). Long term antibiotic therapy and that too associated with several side effects and discomforts have diminished patient compliance with the anti-tubercular chemotherapy. This fact in turn has raised the new deadlier MDR-TB and XDR-TB strains. The whole scenario is a matter of panic and questioning the effectiveness of anti-tubercular antibiotics, immunologic efficacy of century old BCG vaccine and all other medical advents.

Setting up the ‘Heal the World’ Foundation which aims at providing medicine for children and fighting world hunger, drug and alcohol abuse, and child abuse

Tuberculosis (TB) is one of the oldest recorded human diseases known to man, and is still the deadliest killers among bacterial infections (Smith). According to the World Health Organization (WHO), TB is believed to have killed more people worldwide than all the wars and famines combined. TB once viewed as a death sentence in the past, is now a preventable and treatable disease. However, even though this is now a preventable and treatable disease TB continues to kill millions each year. Since the first anti-TB drugs were used to fight TB 60 years ago some TB bacteria have developed resistance to these drugs

BCG is safe and freely available vaccine for prevention of human form of Tuberculosis (TB). Name of this vaccine is given by the name of two scientists Calmette and Guerin. Recently more than 157 Countries have accepted this vaccine as National Immunization schedule.

The biotech firm Amgen Inc. gives much attention and time to the planning process. Because the outcomes for a company like Amgen are often very unsure and many employees are quite sceptical about the use of such a planning, the main issue can be described as follows:

There are many human medical problems that can be controlled by early detection. This program would be incredibly beneficial to the fight of those diseases. Also as a medical benefit is the possibility of gene therapy drugs that could prevent or cure disease. They also could reach as far as to eradicate many of the killers that have plagued mankind for generations. These are some of the reasons that many large companies are attempting to align themselves with other companies that have the technology to capitalize from these new findings. Projections of DNA-based products and technologies in the biotech industry are exceeding $45 billion by the year 2009.

Achieve a median composite eight-year product development cycle by 2010. Deliver two new molecular entity (NME) launches on average per year from 2010. In order to achieve the above objective, ensure that we have 10 or more NMEs in Phase III development by 2010. Development cycle times and quality for small molecules and biologics. Number of NME launches per year. Attrition rates. Number of development projects by phase. Number of in-licensing deals, alliances and acquisitions. R&D investment levels. Improving R&D quality and speed through leading-edge science, effective risk management and decision-making and overall business efficiency. Maximising the value of our biologics business and continuing to build a major presence in this fast-growing sector. Investing in external opportunities to enhance our internal innovation through in-licensing, alliances and acquisitions. 2008 target exceeded for small molecule development cycle times. NME and life-cycle management progressions

Tuberculosis is among the fatal diseases that are spread through the air. It’s contagious, meaning that it spreads from one infected individual to another, and at times it spreads very fast. In addition to being contagious, the disease is an opportunist infection as it takes advantage of those with weak defense mechanism, and especially the ones with terminal diseases like HIV and AIDS. Tuberculosis is therefore among the major concerns for the World Health Organization due to its contagious nature (World Health Organization 1).

India, the second most populous country with over 1.31 billion people, has the highest burden of tuberculosis (TB) in the world, accounting for 20% of the global incidence of TB, and an even higher share of global incidence of multi–drug resistant (MDR) TB. With an estimated 2 million new cases of TB and 5, 00,000 TB-related deaths in India annually, those who got diagnosed with different forms of DR-TB were 35,385 cases but only 20,753 people started on multidrug-resistant TB (MDR-TB) treatment in 2013. The National Tuberculosis Program was launched in 1962, but suffered heavily continuing TB led mortality. Acknowledging this reality, a Revised National Tuberculosis Control Programme (RNTCP) was launched by the Government of India in 1997, however even today it does not comply with World Health Organization (WHO) recommendations.